|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
207,851,000 |
Market
Cap: |
11.60(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$32.18 - $59.82 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
1,788 |
1,788 |
12,464 |
112,865 |
Total Sell Value |
$97,772 |
$97,772 |
$588,604 |
$10,679,455 |
Total People Sold |
2 |
2 |
12 |
18 |
Total Sell Transactions |
2 |
2 |
26 |
68 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Maselli Alessandro |
President & COO |
|
2020-07-24 |
4 |
D |
$81.64 |
$76,742 |
D/D |
(940) |
12,177 |
|
- |
|
Schmidt Kay A |
SVP, Technical Operations |
|
2020-07-24 |
4 |
D |
$81.64 |
$41,147 |
D/D |
(504) |
11,517 |
|
- |
|
Gunther Scott |
SVP, Quality & Reg. Affairs |
|
2020-07-24 |
4 |
D |
$81.64 |
$52,739 |
D/D |
(646) |
12,719 |
|
- |
|
Chiminski John R |
Chair & CEO |
|
2020-07-24 |
4 |
D |
$81.64 |
$542,253 |
D/D |
(6,642) |
207,965 |
|
- |
|
Gunther Scott |
SVP, Quality & Reg. Affairs |
|
2020-06-29 |
4 |
AS |
$71.90 |
$203,318 |
D/D |
(2,824) |
13,365 |
|
42% |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2020-06-25 |
4 |
AS |
$73.00 |
$607,725 |
D/D |
(8,325) |
44,520 |
|
40% |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2020-06-25 |
4 |
D |
$73.00 |
$1,016,890 |
D/D |
(13,930) |
52,845 |
|
- |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2020-06-25 |
4 |
OE |
$24.44 |
$622,541 |
D/D |
22,255 |
59,736 |
|
- |
|
Carroll J Martin |
Director |
|
2020-05-12 |
4 |
A |
$72.29 |
$260,244 |
I/I |
3,600 |
8,527 |
|
- |
|
Carroll J Martin |
Director |
|
2020-05-12 |
4 |
D |
$72.29 |
$260,244 |
I/I |
(3,600) |
0 |
|
- |
|
Carroll J Martin |
Director |
|
2020-05-12 |
4 |
GA |
$0.00 |
$0 |
I/I |
3,600 |
3,600 |
|
- |
|
Carroll J Martin |
Director |
|
2020-05-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,600 |
15,322 |
|
- |
|
Gunther Scott |
SVP, Quality & Reg. Affairs |
|
2020-04-09 |
4 |
A |
$56.46 |
$13,720 |
D/D |
243 |
16,189 |
|
- |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2020-04-09 |
4 |
A |
$56.46 |
$15,752 |
D/D |
279 |
44,520 |
|
- |
|
Buzy Peter L |
President, Gene Therapy |
|
2020-04-09 |
4 |
A |
$56.46 |
$15,018 |
D/D |
266 |
45,950 |
|
- |
|
Schmidt Kay A |
SVP, Technical Operations |
|
2020-04-09 |
4 |
A |
$56.46 |
$12,760 |
D/D |
226 |
12,021 |
|
- |
|
Fasman Steven L |
SVP & General Counsel |
|
2020-04-09 |
4 |
A |
$56.46 |
$21,794 |
D/D |
386 |
63,206 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2020-04-09 |
4 |
A |
$56.46 |
$14,454 |
D/D |
256 |
16,282 |
|
- |
|
Maselli Alessandro |
President & COO |
|
2020-04-09 |
4 |
A |
$56.46 |
$17,785 |
D/D |
315 |
13,117 |
|
- |
|
Joseph Wetteny |
SVP & Chief Financial Officer |
|
2020-04-09 |
4 |
A |
$56.46 |
$19,705 |
D/D |
349 |
46,776 |
|
- |
|
Pravda Ricardo |
SVP & Chief HR Officer |
|
2020-04-09 |
4 |
A |
$56.46 |
$12,760 |
D/D |
226 |
11,072 |
|
- |
|
Flynn Karen |
Pres. Biologics & CCO |
|
2020-04-09 |
4 |
A |
$56.46 |
$20,269 |
D/D |
359 |
35,645 |
|
- |
|
Whitlow Ricci S |
President, CSS |
|
2020-04-09 |
4 |
A |
$56.46 |
$13,550 |
D/D |
240 |
2,704 |
|
- |
|
Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
|
2020-04-09 |
4 |
A |
$56.46 |
$14,905 |
D/D |
264 |
34,509 |
|
- |
|
Lucier Gregory T |
Director |
|
2020-02-13 |
4 |
B |
$59.71 |
$119,420 |
D/D |
2,000 |
40,921 |
2.39 |
19% |
|
822 Records found
|
|
Page 17 of 33 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|